Skip to main content

#152939

Anti-Lewis y/b hapten [NCRC37]

Cat. #152939

Anti-Lewis y/b hapten [NCRC37]

Cat. #: 152939

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Sialyltetraosylceramiden antigen on colorectal tumor cell surface

Class: Monoclonal

Application: ELISA ; FACS ; IHC ; Fn

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Lindy Durrant

Institute: University of Nottingham

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-Lewis y/b hapten [NCRC37]
  • Research fields: Immunology;Tissue-specific biology
  • Clone: NCRC37
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; FACS ; IHC ; Fn
  • Description: Blood group related antigens are a group of carbohydrate determinants present on both glycoproteins and glycolipids. They are usually mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Lewis- y/b is a cell surface carbohydrate blood group antigen expressed at very low levels in normal tissue, but often found to be over-expressed on breast, lung, colon and ovarian cancer cells. Lewis-y antigen, a difucosylatedtetrasaccharide, is found on type 2 blood group oligosaccharides. The antibody, NCRC37, is a pan-reactive, anti-colorectal tumour antibody and binds strongly to coloretal tumour cells and to post mortem cryopreserved tissues of brain, spleen, heat, lung, kidney, testes, oesophagus or stomach. Lewis y antigen has been evaluated as a clinical marker for the diagnosis and prognosis of cholangiocarcinoma, hepatocellular carcinoma and breast cancer.
  • Immunogen: Tissue cultured colorectal tumor cell lines (C170, C146, Colo205, and JW)
  • Isotype: IgG1
  • Myeloma used: NS0
  • Recommended controls: C14 (NCRC10)

Target Details

  • Target: Sialyltetraosylceramiden antigen on colorectal tumor cell surface
  • Tissue cell line specificity: C14 (NCRC10)
  • Target background: Blood group related antigens are a group of carbohydrate determinants present on both glycoproteins and glycolipids. They are usually mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain individuals. Lewis- y/b is a cell surface carbohydrate blood group antigen expressed at very low levels in normal tissue, but often found to be over-expressed on breast, lung, colon and ovarian cancer cells. Lewis-y antigen, a difucosylatedtetrasaccharide, is found on type 2 blood group oligosaccharides. The antibody, NCRC37, is a pan-reactive, anti-colorectal tumour antibody and binds strongly to coloretal tumour cells and to post mortem cryopreserved tissues of brain, spleen, heat, lung, kidney, testes, oesophagus or stomach. Lewis y antigen has been evaluated as a clinical marker for the diagnosis and prognosis of cholangiocarcinoma, hepatocellular carcinoma and breast cancer.

Applications

  • Application: ELISA ; FACS ; IHC ; Fn

Handling

  • Format: Liquid
  • Concentration: 1.14 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Dry ice

References

  • Durrant et al. 2006. Cancer Res. 66(11):5901-9. PMID: 16740730.
  • A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis.
  • Durrant et al. 1993. Hybridoma. 12(6):647-60. PMID: 7507082.
  • Development of second generation monoclonal antibodies recognising Lewisy/b antigen by anti-idiotypic immunisation.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.